Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06997081 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

StatusRecruiting
PhasePhase 2
Started2025-09-16
View on ClinicalTrials.gov ↗

Amendment history

2025-10-02
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2030-10-01→2030-09-30
Completion date2030-10-01→2030-09-30
Start dateestimated 2025-10-01→confirmed 2025-09-16
Study sitesdetails revised at 1 of 1 site
2025-08-12
Study Status v1
Primary completion date2030-08-01→2030-10-01
Completion date2030-08-01→2030-10-01
Start date2025-08-01→2025-10-01
2025-05-21
Original filing
The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
Trial Details
NCT Number NCT06997081
Lead Sponsor University of Miami
Collaborators: Pfizer
Conditions Multiple Myeloma
Enrollment 104 participants
Start Date 2025-09-16
Primary Completion 2030-09-30 (estimated)
Study Completion 2030-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-21